

The way forward in allergy care



“Allergy is a major problem for the 21st century, and this problem is predicted to worsen as this century moves forward.”¹”

The need for action

- 400 million worldwide have allergic rhinitis^{2,3}
- 300 million worldwide have asthma^{2,3}
- Allergic rhinitis is a chronic respiratory disease and is a risk factor for asthma³
- Confirmation of atopic status using allergy testing allows selection of appropriate initial avoidance, pharmacological or desensitization therapy⁴

A proven approach

HYCOR allergy testing provides:

- Quantitative total and specific IgE results with a simple blood test
- Accuracy comparable to other established serum-based tests
- Comprehensive menu including inhalant, food, occupational and environmental allergens
- Demonstrated support for allergen immunotherapy in treatment of perennial allergic rhinitis and asthma⁵

SERUM-BASED IgE TESTING MAY BE INDICATED WHEN:

- The skin test is negative, despite clinical suspicion of allergy
- The suspected allergen is not available as extracts for skin testing (e.g., industrial chemicals)
- Skin conditions (e.g., eczema) preclude skin testing
- Current medications (e.g., antihistamines or tricyclic antidepressants) interfere with skin-test results
- The patient is being evaluated for immunotherapy
- There is a risk of anaphylaxis with exposure to allergens

The way forward in allergy care

Move ahead with HYCOR allergy testing

Accurate and cost-effective allergy testing is readily available from a laboratory near you. Globally, HYCOR partners with leading laboratories, providing them with high-quality products and setting high standards with quality customer service. HYCOR partners with your laboratory to support your practice in the many facets of allergy care:


- Patient education: Materials to increase awareness of allergy diagnosis and treatment
- Website: Online access to educational information through www.whatisallergy.com

Definitive results

Results from prospective clinical study determining immunotherapy treatment safety based on serum-based testing⁵:

- Study objective: Demonstrate safety and efficacy of inhalant allergen immunotherapy based on allergen-specific IgE levels using HYCOR technology
- Study design: Prospective 22-year single-site clinical study on 480 perennial allergic rhinitis patients, including 96 with concomitant asthma
- Conclusion: "Use of quantitative testing technique can be helpful to clinicians and patients by predicting the potential for strong reactions to immunotherapy, and by allowing individualized treatment doses tailored to each patient's specific levels of allergen sensitivities. The result is an effective and safe treatment program."

RESPONSE TO IMMUNOTHERAPY



1. Pawankar R, Baena-Cagnani CE, Bousquet J, et al. WAO J. 2008;(suppl):S4-S17.
2. Bousquet J, Dahl R, Khaltaev N. Allergy. 2007;62:216-223.
3. Bousquet J, Van Cauwenberge P, Khaltaev N. J Allergy Clin Immunol. 2001;108(suppl 1):S147-S334.
4. Dykewicz MS, Fineman S, Skoner DP, et al. Ann Allergy Asthma Immunol. 1998;81:478-518.
5. Yeoh KH, Wang DY, Gordon BR. Otolaryngol Head Neck Surg. 2004;131:673-678.

This information is subject to change without notice.



HYCOR Biomedical Inc.
7272 Chapman Avenue
Garden Grove, CA 92841
USA

Tel: +1 800 382 2527
Fax: +1 714 933 3222

HYCOR Biomedical Ltd.
Pentlands Science Park
Bush Loan, Penicuik
Edinburgh EH26 0PL
United Kingdom

Tel: +44 (0)131 445 7111
Fax: +44 (0)131 445 7112

www.hycorbiomedical.com